HONEDRA® (formerly CLBS12)

Study Information

A Phase 2 study is underway in Japan evaluating an autologous CD34 cell therapy (HONEDRA®) for the treatment of no-option critical limb ischemia (CLI). For more information on this study, please visit www2.tri-kobe.org/clbs12.

Status: Active - Enrolling